Primary Endpoint Achieved in CBL-0202DD Phase 2 Trial—CBL-514 delivered statistically significant pain reduction across both FAS and PP populations compared with placebo. Expansion Opportunity Beyond Dercum's Disease—Study findings support the potential development of CBL-514 for...
Hence then, the article about caliway announces positive phase 2 results of cbl 514 in dercum s disease achieving primary endpoint with statistically significant and sustained pain reduction was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum's Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction )
Also on site :
- Jordan Peele’s Monkeypaw Productions and Universal Film Team With American Cinematheque and Beyond Fest for ‘No Drama’ Initiative (EXCLUSIVE)
- VMAs Producer Van Toffler on Nirvana & George Michael Tributes at 2026 Awards and Why the VMAs Are Best at Their Most ‘Age, Genre & Color Blind’
- ‘America’s Got Talent’ 2026 Finale Moves to New Time Slot Tonight: Here’s How to Watch